# PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

> **NCT01212757** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 488 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Apremilast 20mg
- **DRUG:** Apremilast 30mg
- **DRUG:** Placebo + 20 mg Apremilast
- **DRUG:** Placebo + 30 mg Apremilast

## Key facts

- **NCT ID:** NCT01212757
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-27
- **Primary completion:** 2012-07-26
- **Final completion:** 2017-01-25
- **Target enrollment:** 488 (ACTUAL)
- **Last updated:** 2020-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212757, "PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01212757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*